<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               14 CLINICAL STUDIES<BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.1 Updated Adjuvant Treatment of Early  Breast Cancer<BR>                     <BR>                        <BR>In a multicenter study enrolling over 8,000 postmenopausal women with resected, receptor-positive early breast cancer, one of the following treatments was randomized in a double-blind manner:<BR> <BR>Option 1:<BR> <BR>A.     tamoxifen for 5 years<BR>B.     Letrozole tablets for 5 years<BR>C.     tamoxifen for 2 years followed by letrozole tablets for 3 years<BR>D.     Letrozole tablets for 2 years followed by tamoxifen for 3 years <BR> <BR>Option 2:<BR><BR>                        <BR>A.     tamoxifen for 5 years<BR>B.     Letrozole tablets for 5 years The study in the adjuvant setting, BIG 1-98 was designed to answer two primary questions: whether letrozole tablets for 5 years were superior to tamoxifen for 5 years (Primary Core Analysis) and whether switching endocrine treatments at 2 years was superior to continuing the same agent for a total of 5 years (Sequential Treatments Analysis). Selected baseline characteristics for the study population are shown in Table 5.<BR>                        The primary endpoint of this trial was disease-free survival (DFS) (i.e., interval between randomization and earliest occurrence of a local, regional, or distant recurrence, or invasive contralateral breast cancer, or death from any cause). The secondary endpoints were overall survival (OS), systemic disease-free survival (SDFS), invasive contralateral breast cancer, time to breast cancer recurrence (TBR) and time to distant metastasis (TDM).<BR>                        The Primary Core Analysis (PCA) included all patients and all follow-up in the monotherapy arms in both randomization options, but follow-up in the two sequential treatments arms was truncated 30 days after switching treatments. The PCA was conducted at a median treatment duration of 24 months and a median follow-up of 26 months. Letrozole tablets were superior to tamoxifen in all endpoints except overall survival and contralateral breast cancer [e.g., DFS: hazard ratio, HR 0.79; 95% CI (0.68, 0.92); P=0.002; SDFS: HR 0.83; 95% CI (0.70, 0.97); TDM: HR 0.73; 95% CI (0.60, 0.88); OS: HR 0.86; 95% CI (0.70, 1.06). <BR>                        In 2005, based on recommendations by the independent Data Monitoring Committee, the tamoxifen arms were unblinded and patients were allowed to complete initial adjuvant therapy with letrozole tablets (if they had received tamoxifen for at least 2 years) or to start extended adjuvant treatment with letrozole tablets (if they had received tamoxifen for at least 4.5 years) if they remained alive and disease-free. In total, 632 patients crossed to letrozole tablets or another aromatase inhibitor. Approximately 70% (448) of these 632 patients crossed to letrozole tablets to complete initial adjuvant therapy and most of these crossed in years 3 to 4. All of these patients were in Option 1. A total of 184 patients started extended adjuvant therapy with letrozole tablets (172 patients) or with another aromatase inhibitor (12 patients). To explore the impact of this selective crossover, results from analyses censoring follow-up at the date of the selective crossover (in the tamoxifen arm) are presented for the Monotherapy Arms Analysis (MAA).<BR>                        The PCA allowed the results of letrozole tablets for 5 years compared with tamoxifen for 5 years to be reported in 2005 after a median follow-up of only 26 months. The design of the PCA is not optimal to evaluate the effect of letrozole tablets after a longer time (because follow-up was truncated in two arms at around 25 months). The Monotherapy Arms Analysis (ignoring the two sequential treatment arms) provided follow-up equally as long in each treatment and did not over-emphasize early recurrences as the PCA did. The MAA thus provides the clinically appropriate updated efficacy results in answer to the first primary question, despite the confounding of the tamoxifen reference arm by the selective crossover to letrozole tablets. The updated results for the MAA are summarized in Table 6. Median follow-up for this analysis is 73 months.<BR>                        The Sequential Treatments Analysis (STA) addresses the second primary question of the study. The primary analysis for the Sequential Treatments Analysis (STA) was from switch (or equivalent time-point in monotherapy arms) + 30 days (STA-S) with a two-sided test applied to each pair-wise comparison at the 2.5% level. Additional analyses were conducted from randomization (STA-R) but these comparisons (added in light of changing medical practice) were under-powered for efficacy.<BR>                        <BR><BR>                        Table 5: Adjuvant Study - Patient and Disease Characteristics (ITT Population)<BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2" align="center"><BR>                                    <content styleCode="bold">Primary Core Analysis </content><BR>                                    <br/><BR>                                    <content styleCode="bold">(PCA)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2" align="center"><BR>                                    <content styleCode="bold">Monotherapy Arms Analysis (MAA)</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">&#160;</content><BR>                                    <br/><BR>                                    <content styleCode="bold">&#160;</content><BR>                                    <br/><BR>                                    <content styleCode="bold">Characteristic</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=4003</content><BR>                                    <br/><BR>                                    <content styleCode="bold">n (%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=4007</content><BR>                                    <br/><BR>                                    <content styleCode="bold">n (%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2463</content><BR>                                    <br/><BR>                                    <content styleCode="bold">n (%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2459</content><BR>                                    <br/><BR>                                    <content styleCode="bold">n (%)</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">Age (median, years)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">61<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">61<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">61<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">61<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">Age range (years)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">38-89<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">39-90<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">38-88<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">39-90<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">Hormone receptor status (%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ER+ and/or PgR+<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">99.7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">99.7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">99.7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">99.7<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Both unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.3<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.3<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.3<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.3<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">Nodal status (%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Node negative<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">52<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">52<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">50<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">52<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Node positive<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">41<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">41<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">43<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">41<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Nodal status unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">7<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">Prior adjuvant chemotherapy (%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">24<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">24<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">24<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">24<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> Table 6: Updated Adjuvant Study Results - Monotherapy Arms Analysis <BR>                        <BR>                        <BR>                           (Median Follow-up 73 Months)<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2" align="center"><BR>                                    <content styleCode="bold">Letrozole tablets<br/>N=2463</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2" align="center"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2459</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Hazard ratio</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Events</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">5-year rate</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Events</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">5-year rate</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">(95% CI)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content><BR>                                    </content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">Disease-free survival<sup>1</sup><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">445 (18.1)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">87.4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">500 (20.3)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">84.7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.87 (0.76, 0.99)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.03<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Censor<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">445<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">87.4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">483<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">84.2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.84 (0.73, 0.95)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0 positive nodes<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">165<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">92.2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">189<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">90.3<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.88 (0.72, 1.09)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">1-3 positive nodes<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">151<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">85.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">163<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">83.0<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.85 (0.68, 1.06)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&gt;=4 positive nodes<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">123<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">71.2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">142<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">62.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.81 (0.64, 1.03)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Adjuvant chemotherapy<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">119<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">86.4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">150<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">80.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.77 (0.60, 0.98)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2">No chemotherapy<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">326<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">87.8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">350<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">86.1<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.91 (0.78, 1.06)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">Systemic DFS<sup>2</sup><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">401<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">88.5<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">446<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">86.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.88 (0.77, 1.01)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">Time to distant metastasis<sup>3</sup><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">257<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">92.4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">298<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">90.1<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.85 (0.72, 1.00)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Adjuvant chemotherapy<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">84<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">-<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">109<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">-<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160;0.75 (0.56, 1.00)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">No chemotherapy<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">173<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">-<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">189<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">-<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.90 (0.73, 1.11)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">Distant DFS<sup>4</sup><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">385<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">89.0<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">432<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">87.1<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.87 (0.76, 1.00)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">Contralateral breast cancer<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">34<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">99.2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">44<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">98.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.76 (0.49, 1.19)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">Overall survival<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">303<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">91.8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">343<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">90.9<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.87 (0.75, 1.02)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="3">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Censor<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">303<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">91.8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">338<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">90.1<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.82 (0.70, 0.96)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0 positive nodes<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">107<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">95.2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">121<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">94.8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.90 (0.69, 1.16)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">1-3 positive nodes<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">99<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">90.8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">114<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">90.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.81 (0.62, 1.06)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&gt;=4 positive nodes<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">92<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">80.2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">104<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">73.6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.86 (0.65, 1.14)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Adjuvant chemotherapy<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">76<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">91.5<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">96<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">88.4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.79 (0.58, 1.06)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">No chemotherapy<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ITT<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">227<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">91.9<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">247<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">91.8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.91 (0.76, 1.08)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="10">Definition of:<br/><BR>                                    <sup>1&#160;</sup>Disease-free survival: Interval from randomization to earliest event of invasive loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death without a prior event<br/><BR>                                    <sup>2&#160;</sup>Systemic disease-free survival: Interval from randomization to invasive regional recurrence, distant metastasis, or death without a prior cancer event<br/><BR>                                    <sup>3</sup>&#160;Time to distant metastasis: Interval from randomization to distant metastasis<br/><BR>                                    <sup>4</sup>&#160;Distant disease-free survival: Interval from randomization to earlier event of relapse in a distant site or death from any cause <br/>ITT analysis ignores selective crossover in tamoxifen arms<br/>Censored analysis censors follow-up at the date of selective crossover in 632 patients who crossed to letrozole tablets or another aromatase inhibitor after the tamoxifen arms were unblinded in 2005<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                                 <td valign="top" styleCode="Rrule"/><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Figure 1 shows the Kaplan-Meier curves for Disease-Free Survival Monotherapy Analysis<BR>                        <BR>                           Figure 1 Disease-Free Survival (Median follow-up 73 months, ITT Approach)<BR>                        <BR>                        <BR><BR>                        <BR><BR>                        <BR>                        <BR>DFS events defined as loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death from any cause (i.e., definition excludes second non-breast primary cancers).<BR><BR>                        The medians of overall survival for both arms were not reached for the Monotherapy Arms Analysis (MAA). There was no statistically significant difference in overall survival. The hazard ratio for survival in the letrozole tablets arm compared to the tamoxifen arm was 0.87, with 95% CI (0.75, 1.02) (see Table 6).<BR>                        There were no significant differences in DFS, OS, SDFS, and Distant DFS from switch in the Sequential Treatments Analysis with respect to either monotherapy (e.g., [Tamoxifen 2 years followed by] letrozole tablets 3 years versus tamoxifen beyond 2 years, DFS HR 0.89; 97.5% CI 0.68, 1.15 and [letrozole tablets 2 years followed by] tamoxifen 3 years versus letrozole tablets beyond 2 years, DFS HR 0.93; 97.5% CI 0.71, 1.22).<BR>                        There were no significant differences in DFS, OS, SDFS, and Distant DFS from randomization in the Sequential Treatments Analyses.<BR>                     <BR>                     <BR>                     <BR>                        <BR>                           letrozole graph<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months<BR>                     <BR>                        <BR>A double-blind, randomized, placebo-controlled trial of letrozole tablets was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen.<BR> <BR>The planned duration of treatment for patients in the study was 5 years, but the trial was terminated early because of an interim analysis showing a favorable letrozole tablets effect on time without recurrence or contralateral breast cancer. At the time of unblinding, women had been followed for a median of 28 months, 30% of patients had completed 3 or more years of follow-up and less than 1% of patients had completed 5 years of follow-up.<BR> <BR>Selected baseline characteristics for the study population are shown in Table 7.<BR> <BR><BR>                        Table 7: Selected Study Population Demographics (Modified ITT Population)<BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2582</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Placebo</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=2586</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Hormone Receptor Status (%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ER+ and/or PgR+<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">98<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">98<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Both Unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">2<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Nodal Status (%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Node Negative<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">50<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">50<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Node Positive<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">46<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">46<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Nodal Status Unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">4<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Chemotherapy</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">46<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">46<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Table 8 shows the study results. Disease-free survival was measured as the time from randomization to the earliest event of loco-regional or distant recurrence of the primary disease or development of contralateral breast cancer or death. DFS by hormone receptor status, nodal status and adjuvant chemotherapy were similar to the overall results. Data were premature for an analysis of survival.<BR>                        <BR>                           Table 8: Extended Adjuvant Study Results<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Letrozole tablets<br/>N = 2582</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Placebo <br/>N = 2586</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">Hazard Ratio <br/>(95% CI)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Disease Free Survival (DFS)<sup>1</sup>&#160;Events</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">122 (4.7%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">193 (7.5%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.62 (0.49, 0.78)<sup>2</sup><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.00003<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Local Breast &#160;&#160;Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">9<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">22<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Local Chest Wall Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">2<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Regional Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">7<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">4<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Distant Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">55<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">92<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.61 (0.44, 0.84)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">0.003<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Contralateral Breast Cancer<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">19<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">29<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Deaths Without Recurrence or Contralateral Breast Cancer<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">30<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">38<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="6">CI = confidence interval for hazard ratio. Hazard ratio of less than 1.0 indicates difference in favor of letrozole tablets (lesser&#160;risk of recurrence); hazard ratio greater than 1.0 indicates difference in favor of placebo (higher risk of recurrence with letrozole tablets).<br/><BR>                                    <sup>1</sup>&#160;First event of loco-regional recurrence, distant relapse, contralateral breast cancer or death from any cause <br/><BR>                                    <sup>2&#160;</sup>Analysis stratified by receptor status, nodal status and prior adjuvant chemotherapy (stratification factors as at randomization). <content styleCode="italics">P</content>-value based on stratified logrank test.<content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.3 Updated Analyses of Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months<BR>                     <BR>                        <BR><BR>                        <BR>                           Table 9:  Update of Extended Adjuvant Study Results<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <content styleCode="bold"><BR>                                       <br/>N = 2582</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Placebo <br/>N = 2586</content><BR>                                    <br/><BR>                                    <content styleCode="bold">(%)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Hazard Ratio<sup>1 </sup><BR>                                       <br/>(95% CI)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value<sup>2</sup><BR>                                    </content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Disease Free Survival (DFS) events<sup>3</sup><BR>                                    </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">344 (13.3)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">402 (15.5)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.89 (0.77, 1.03)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.12<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Breast cancer recurrence</content><BR>                                    <br/>(Protocol definition of DFS events<sup>4</sup>) <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">209<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">286<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.75 (0.63, 0.89)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.001<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Local Breast Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">15<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">44<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Local Chest Wall Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">14<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Regional Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">10<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">8<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Distant Recurrence<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">140<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">167<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Distant recurrence (first or subsequent events)<br/>Contralateral Breast Cancer<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <br/>142<br/>37<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <br/>169<br/>53<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.88 (0.70, 1.10)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.246<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Deaths Without Recurrence or Contralateral Breast Cancer<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">135<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">116<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="6"><BR>                                    <sup>1 </sup>Adjusted by receptor status, nodal status and prior chemotherapy<br/><BR>                                    <sup>2</sup> Stratified logrank test, stratified by receptor status, nodal status and prior chemotherapy<br/><BR>                                    <sup>3</sup> DFS events defined as earliest of loco-regional recurrence, distant metastasis, contralateral breast cancer or death from any cause, and ignoring switches to letrozole tablets in 60% of the placebo arm.<br/><BR>                                    <sup>4</sup> Protocol definition does not include deaths from any cause&#160;<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Updated analyses were conducted at a median follow-up of 62 months. In the letrozole tablets arm, 71% of the patients were treated for a least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. After the unblinding of the study at a median follow-up of 28 months, approximately 60% of the selected patients in the placebo arm opted to switch to letrozole tablets.<BR>                        <BR>In this updated analysis shown in Table 9, letrozole tablets significantly reduced the risk of breast cancer recurrence or contralateral breast cancer compared with placebo (HR 0.75; 95% CI 0.63, 0.89; P=0.001). However, in the updated DFS analysis (interval between randomization and earliest event of loco-regional recurrence, distant metastasis, contralateral breast cancer, or death from any cause) the treatment difference was heavily diluted by 60% of the patients in the placebo arm switching to letrozole tablets and accounting for 64% of the total placebo patient- years of follow-up. Ignoring these switches, the risk of DFS event was reduced by a non-significant 11% (HR 0.89; 95% CI 0.77, 1.03). There was no significant difference in distant disease-free survival or overall survival.<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.4 First-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                        <BR>A randomized, double-blind, multinational trial compared letrozole tablets 2.5 mg with tamoxifen 20 mg in 916 postmenopausal patients with locally advanced (Stage IIIB or loco-regional recurrence not amenable to treatment with surgery or radiation) or metastatic breast cancer. Time to progression (TTP) was the primary endpoint of the trial. Selected baseline characteristics for this study are shown in Table 10.<BR> <BR><BR>                        Table 10: Selected Study Population Demographics<BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Baseline Status</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets </content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=458</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=458</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Stage of Disease</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">IIIB<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">7%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">IV<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">93%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">92%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Receptor Status</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ER and PgR&#160;Positive<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">38%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">41%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ER or PgR Positive<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">26%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">26%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Both Unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">34%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">33%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">ER<sup>-</sup> or PgR<sup>-</sup>/Other Unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&lt;1%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Previous Antiestrogen Therapy</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Adjuvant<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">19%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">18%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">None<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">81%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">82%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Dominant Site of Disease</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Soft Tissue<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">25%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">25%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Bone<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">32%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">29%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Viscera<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">43%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">46%<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR> <BR>Letrozole tablets were superior to tamoxifen in TTP and rate of objective tumor response (see Table 11).<BR> <BR>Table 11 summarizes the results of the trial, with a total median follow-up of approximately 32 months. (All analyses are unadjusted and use 2-sided P-values.)<BR>                           Table 11: Results of First-Line Treatment of Advanced Breast Cancer<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets </content><BR>                                    <br/><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=453</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">20 mg</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=454</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Hazard or Odds</content><BR>                                    <br/><BR>                                    <content styleCode="bold">Ratio (95% CI)</content><BR>                                    <br/><BR>                                    <content styleCode="bold"><BR>                                       <content styleCode="italics">P</content>-Value (2-Sided)</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">9.4 months<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6.0 months<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.72 (0.62, 0.83)<sup>1</sup><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="italics">P</content>&lt;0.0001<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Objective Response Rate</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(CR + PR)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">145 (32%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">95 (21%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">1.77 (1.31, 2.39)<sup>2</sup><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="italics">P</content>=0.0002<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(CR)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">42 (9%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">15 (3%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">2.99 (1.63, 5.47)<sup>2</sup><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="italics">P</content>=0.0004<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Duration of Objective Response</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Median<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">18 months <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">16 months <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(N=145)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(N=95)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Overall Survival</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">35 months <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">32 months<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(N=458)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(N=458)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="italics">P</content>=0.5136<sup>3</sup><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR><BR>                        1 Hazard ratio<BR><BR>                        2 Odds ratio<BR><BR>                        3 Overall logrank test<BR> <BR>Figure 2 shows the Kaplan-Meier curves for TTP<BR>.<BR><BR>                        Figure 2  Kaplan-Meier Estimates of Time to Progression (Tamoxifen Study)<BR>                        <BR><BR>                        <BR>                        <BR>Table 12 shows results in the subgroup of women who had received prior antiestrogen adjuvant therapy, Table 13, results by disease site and Table 14, the results by receptor status.<BR><BR>                        <BR> <BR><BR>                        Table 12: Efficacy in Patients Who Received Prior Antiestrogen Therapy<BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Variable</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets &#160;</content><BR>                                    <br/><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=84</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">20 mg</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=83</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Median Time to Progression</content> (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">8.9 months (6.2, 12.5) <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">5.9 months (3.2, 6.2)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Hazard Ratio for TTP (95% CI) <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.60 (0.43, 0.84)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Objective Response Rate</content><BR>                                    <content styleCode="bold"/><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(CR + PR)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">22 (26%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">7 (8%)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Odds Ratio for&#160;Response (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">3.85 (1.50, 9.60)<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR> <BR>Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole tablets; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<BR> Table 13: Efficacy by Disease Site<BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets &#160;</content><BR>                                    <br/><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">20 mg</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Dominant Disease Site</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Soft Tissue:</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=113<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=115<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Median TTP<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">12.1 months<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6.4 months<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Objective Response Rate<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">50%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">34%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Bone:</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=145<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=131<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Median TTP<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">9.5 months<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6.3 months<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Objective Response Rate<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">23%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">15%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" colspan="2"><BR>                                    <content styleCode="bold">Viscera:</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=195<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=208<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Median TTP<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">8.3 months<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">4.6 months<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">&#160; </content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Objective Response Rate<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">28%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">17%<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Table 14: Efficacy by Receptor Status<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Variable</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">tamoxifen</content><BR>                                    <br/><BR>                                    <content styleCode="bold">20 mg</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Receptor Positive</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=294<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=305<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Median Time to&#160;Progression (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">9.4 months (8.9, 11.8)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6.0 months (5.1, 8.5)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Hazard Ratio for TTP (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">0.69 (0.58, 0.83)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Objective Response Rate (CR+PR)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">97 (33%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">66 (22%)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Odds Ratio for Response (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">1.78 (1.20, 2.60)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Receptor Unknown</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=159<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">N=149<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Median Time to&#160;Progression (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">9.2 months (6.1, 12.3)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">6.0 months (4.1, 6.4)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Hazard Ratio for TTP (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160;0.77 (0.60, 0.99)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Objective Response Rate (CR+PR)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">48 (30%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">29 (20%)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160; Odds Ratio for Response (95% CI)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">1.79 (1.10, 3.00)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR> <BR>Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole tablets; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<BR> <BR>Figure 3 shows the Kaplan-Meier curves for survival.<BR> <BR><BR>                        Figure 3  Survival by Randomized Treatment Arm<BR>                        <BR><BR>                        <BR>                        <BR><BR>                        Legend: Randomized letrozole tablets: n=458, events 57%, median overall survival 35 months (95% CI 32 to 38 months)<BR> <BR>Randomized tamoxifen: n=458, events 57%, median overall survival 32 months (95% CI 28 to 37 months)<BR> <BR>Overall logrank P=0.5136 (i.e., there was no significant difference between treatment arms in overall survival).<BR><BR>                        <BR>The median overall survival was 35 months for the letrozole tablets group and 32 months for the tamoxifen group, with a P-value 0.5136. Study design allowed patients to cross over upon progression to the other therapy. Approximately 50% of patients crossed over to the opposite treatment arm and almost all patients who crossed over had done so by 36 months. The median time to crossover was 17 months (letrozole tablets to tamoxifen) and 13 months (tamoxifen to letrozole tablets). In patients who did not cross over to the opposite treatment arm, median survival was 35 months with letrozole tablets (n=219, 95% CI 29 to 43 months) vs 20 months with tamoxifen (n=229, 95% CI 16 to 26 months).<BR>                     <BR>                     <BR>                        <BR>                           letrozole graph<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           letrozole graph<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     14.5 Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                        Letrozole tablets was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with letrozole tablets 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response).<BR>                        Two large randomized, controlled, multinational (predominantly European) trials were conducted in patients with advanced breast cancer who had progressed despite antiestrogen therapy. Patients were randomized to letrozole tablets 0.5 mg daily, letrozole tablets 2.5 mg daily, or a comparator (megestrol acetate 160 mg daily in one study; and aminoglutethimide 250 mg b.i.d. with corticosteroid supplementation in the other study). In each study over 60% of the patients had received therapeutic antiestrogens, and about one-fifth of these patients had had an objective response. The megestrol acetate controlled study was double-blind; the other study was open label. Selected baseline characteristics for each study are shown in Table 15.<BR>                         Table 15: Selected Study Population Demographics<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Parameter</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">megestrol acetate</content><BR>                                    <br/><BR>                                    <content styleCode="bold">study</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center"><BR>                                    <content styleCode="bold">aminoglutethimide</content><BR>                                    <br/><BR>                                    <content styleCode="bold">study</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">No. of Participants</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">552<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">557<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Receptor Status</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; ER/PR Positive<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">57%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">56%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; ER/PR Unknown<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">43%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">44%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Previous Therapy</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; Adjuvant Only<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">33%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">38%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; Therapeutic +/- Adj.<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">66%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">62%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Sites of Disease</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; Soft Tissue<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">56%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">50%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; Bone<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">50%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">55%<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160;&#160;&#160;&#160;&#160; Viscera<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">40%<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" align="center">44%<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>Confirmed objective tumor response (complete response plus partial response) was the primary endpoint of the trials. Responses were measured according to the Union Internationale Contre le Cancer (UICC) criteria and verified by independent, blinded review. All responses were confirmed by a second evaluation 4-12 weeks after the documentation of the initial response.<BR>                        Table 16 shows the results for the first trial, with a minimum follow-up of 15 months, that compared letrozole tablets 0.5 mg, letrozole tablets 2.5 mg, and megestrol acetate 160 mg daily. (All analyses are unadjusted.)<BR>                        <BR>                           Table 16: Megestrol Acetate Study Results<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">0.5 mg </content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=188</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">2.5 mg </content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=174</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">megestrol </content><BR>                                    <br/><BR>                                    <content styleCode="bold">acetate </content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=190</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule" align="center"><BR>                                    <content styleCode="bold">Objective Response (CR + PR)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">22 (11.7%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">41 (23.6%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">31 (16.3%)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Duration of Response</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">552 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">(Not reached)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">561 days<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">154 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">170 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">168 days<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Survival</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">633 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">730 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">659 days<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Odds Ratio for Response</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2">Letrozole tablets 2.5:&#160;Letrozole tablets 0.5=2.33 <br/>(95% CI: 1.32, 4.17); <content styleCode="italics">P</content>=0.004*<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Letrozole tablets 2.5: megestrol=1.58 <br/>(95% CI: 0.94, 2.66); <content styleCode="italics">P</content>=0.08*<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Relative Risk of Progression</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2">Letrozole tablets 2.5:&#160;Letrozole tablets 0.5=0.81 <br/>(95% CI: 0.63, 1.03); <content styleCode="italics">P</content>=0.09*<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Letrozole tablets 2.5:&#160;megestrol=0.77 <br/>(95% CI: 0.60, 0.98);&#160;<content styleCode="italics">P</content>=0.03* <br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table>* two-sided <BR><BR><BR>P-value<BR> <BR>The Kaplan-Meier curves for progression for the megestrol acetate study are shown in Figure 4.<BR> <BR><BR>                        Figure 4 Kaplan-Meier Estimates of Time to Progression (Megestrol Acetate Study)<BR>                        <BR> <BR><BR>                         The results for the study comparing letrozole tablets to aminoglutethimide, with a minimum follow-up of 9 months, are shown in Table 17. (Unadjusted analyses are used.)<BR>                          <BR>                        <BR>                           Table 17: Aminoglutethimide Study Results<BR>                        <BR>                        <BR><BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" cellspacing="0" cellpadding="0" border="0" width="100%"><BR>                           <tbody><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule">&#160; <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets </content>&#160;<br/><BR>                                    <content styleCode="bold">0.5 mg</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=193</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">Letrozole tablets</content><BR>                                    <br/><BR>                                    <content styleCode="bold">2.5 mg</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=185</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule"><BR>                                    <content styleCode="bold">aminoglutethimide</content><BR>                                    <br/><BR>                                    <content styleCode="bold">N=179</content><BR>                                    <br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Objective Response (CR&#160;+&#160;PR)</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">34 (17.6%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">34 (18.4%)<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">22 (12.3%)<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Duration of Response</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">619 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">706 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">450 days<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Time to Progression</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">103 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">123 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">112 days<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Median Survival</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">636 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">792 days<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">592 days<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr styleCode="Botrule"><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Odds Ratio for Response</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2">Letrozole tablets 2.5:<br/>Letrozole tablets 0.5=1.05<br/>(95% CI: 0.62, 1.79);<content styleCode="italics"> P</content>=0.85*<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Letrozole tablets 2.5:<br/>aminoglutethimide=1.61 <br/>(95% CI: 0.90, 2.87); <content styleCode="italics">P</content>=0.11*<br/><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td valign="top" styleCode="Lrule Rrule"><BR>                                    <content styleCode="bold">Relative Risk of Progression</content><BR>                                    <br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule" colspan="2">Letrozole tablets 2.5:<br/>Letrozole tablets 0.5=0.86<br/>(95% CI: 0.68, 1.11); <content styleCode="italics">P</content>=0.25*<br/><BR>                                 </td><BR>                                 <td valign="top" styleCode="Rrule">Letrozole tablets 2.5:&#160;<br/>aminoglutethimide=0.74<br/>(95% CI: 0.57, 0.94); <content styleCode="italics">P</content>=0.02*<br/><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR> *two-sided P-value<BR>                        <BR>The Kaplan-Meier curves for progression for the aminoglutethimide study is shown in Figure 5<BR> <BR><BR>                        Figure 5 Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study)<BR>                        <BR> <BR><BR>                        <BR>                     <BR>                     <BR>                     <BR>                        <BR>                           letrozole graph<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                     <BR>                        <BR>                           letrozole graph<BR>                           <BR>                              <BR>                           <BR>                        <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>